Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial

American Heart Journal
Nicolas M Van MieghemGeorge D Dangas

Abstract

Transcatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate- to high-risk AF patients, the direct factor Xa inhibitor edoxaban is noninferior to vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism with less bleeding and cardiovascular deaths. ENVISAGE-TAVI AF (NCT02943785) is a multinational, multicenter, prospective, randomized, open-label, blinded end point evaluation study comparing edoxaban to VKA-based therapy in approximately 1,400 patients with an indication for chronic oral anticoagulation after successful transfemoral TAVR. The coprimary end points are to assess the differential effects of the 2 treatments (a) on net adverse clinical events (the composite of all-cause death, myocardial infarction, ischemic stroke, systemic thromboembolism, valve thrombosis, and major bleeding events) and (b) on major bleeding. Twelve hours to 5 days after successful TAVR, patients will be randomized to 60 mg daily oral edoxaban or any VKA (internat...Continue Reading

References

Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Oct 22, 2010·The New England Journal of Medicine·Martin B LeonUNKNOWN PARTNER Trial Investigators
Jun 7, 2011·The New England Journal of Medicine·Craig R SmithUNKNOWN PARTNER Trial Investigators
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Feb 4, 2012·Journal of the American College of Cardiology·David R HolmesJames D Thomas
Mar 20, 2012·The American Journal of Cardiology·Rutger-Jan NuisPeter P de Jaegere
Jun 19, 2012·The Canadian Journal of Cardiology·John WebbSamuel Lichtenstein
Aug 28, 2012·European Heart Journal·UNKNOWN Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC)Marian Zembala
Oct 31, 2013·The American Journal of Cardiology·Eric DurandHélène Eltchaninoff
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Apr 1, 2014·The New England Journal of Medicine·David H AdamsUNKNOWN U.S. CoreValve Clinical Investigators
Dec 20, 2014·Journal of the American College of Cardiology·Philippe GénéreuxMartin B Leon
Feb 6, 2015·Thrombosis and Haemostasis·Vincent J NijenhuisJurriën M ten Berg
Dec 18, 2015·The New England Journal of Medicine·Jochen ReinöhlManfred Zehender
Apr 5, 2016·The New England Journal of Medicine·Martin B LeonUNKNOWN PARTNER 2 Investigators
Dec 6, 2016·JACC. Cardiovascular Interventions·Julia SeegerJochen Wöhrle
Feb 18, 2017·Circulation·Anthony P CarnicelliUNKNOWN ENGAGE AF-TIMI 48 Investigators

❮ Previous
Next ❯

Citations

Jan 12, 2019·Circulation. Cardiovascular Interventions·Paul GuedeneyGeorge D Dangas
Nov 10, 2017·Pharmacotherapy·Bethany A KalichIan B Hollis
Oct 22, 2019·Journal of Cardiovascular Pharmacology·Abby K HendricksRachael A Scott
Jul 9, 2020·The New England Journal of Medicine·Stefan StojkovicAlexander Niessner
Jun 20, 2019·Frontiers in Cardiovascular Medicine·Roberto ValvoMarco Barbanti
Jan 19, 2020·Nature Reviews. Cardiology·Davide CapodannoDominick J Angiolillo
Jul 9, 2020·The New England Journal of Medicine·George D DangasStephan Windecker
May 10, 2020·Interventional Cardiology·Antonio Greco, Davide Capodanno
Jun 15, 2019·Expert Review of Cardiovascular Therapy·Antonio GrecoDavide Capodanno
Jan 12, 2021·Circulation. Cardiovascular Interventions·Toby RogersRon Waksman
Feb 25, 2021·European Journal of Preventive Cardiology·Leonardo BencivengaGiuseppe Rengo
Mar 25, 2021·Thrombosis and Haemostasis·Philipp MourikisAmin Polzin
Apr 26, 2020·Cardiology in Review·Filipe FerrariRicardo Stein
Oct 28, 2019·Annales de cardiologie et d'angéiologie·P Guedeney, J-P Collet
Apr 26, 2021·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Jan SteffelUNKNOWN External reviewers
May 6, 2021·Wiener medizinische Wochenschrift·Frederik VossJens Litmathe
Jul 19, 2021·JACC. Cardiovascular Interventions·Romain DidierUNKNOWN STOP-AS and France-TAVI
Aug 7, 2021·JACC. Cardiovascular Interventions·Davide CapodannoDominick J Angiolillo
Aug 28, 2021·The New England Journal of Medicine·Nicolas M Van MieghemUNKNOWN ENVISAGE-TAVI AF Investigators
Nov 2, 2020·JACC. Cardiovascular Interventions·Hideyuki KawashimaUNKNOWN OCEAN-TAVI Investigator
Nov 21, 2020·JACC. Cardiovascular Interventions·Jurrien M Ten Berg, Jorn Brouwer
Oct 30, 2021·The Annals of Thoracic Surgery·Hao-Tse ChiuChih-Yuan Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.